3
Announcements
Trials
Browse
Landscape
Status
Completed
40
Terminated
20
Recruiting
16
Active not recruiting
12
Withdrawn
5
Not yet recruiting
2
Available
2
Unknown
1
Suspended
1
No longer available
1
Sponsor Class
INDUSTRY
2
Study Type
Expanded_access
2
Sponsor
Cancer Type
Myeloid
2
Sarcoma
1
Plasma cell
1
Lymphoid
1
Gynecologic
1
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
5
Pancreatic Neoplasms
5
Multiple Myeloma
5
Melanoma
5
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Primary Myelofibrosis
2
Non-Muscle Invasive Bladder Neoplasms
2
Neuroblastoma
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Interventions
selinexor
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Available
×
INDUSTRY
×
Primary Myelofibrosis
×
Clear all
NCT07215832
2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT04745637
2025-11-18
Managed Access Programs for INC424, Ruxolitinib
Novartis
Available